I N T R O D U C T I O N
Autosomal dominant polycystic kidney disease (ADPKD) is the most common renal hereditary disorder, often leading to endstage renal disease between the fourth and seventh decade of life [1] . Other symptoms that ADPKD patients may encounter include pain, urolithiasis and cyst haemorrhage [2] . In addition, renal cyst infection may complicate ADPKD, a complication that is often difficult to treat and may lead to mortality [3, 4] . Renal cyst infection should be considered in an ADPKD patient who presents with acute abdominal pain and fever. Cyst infection may be the result of an ascending urinary tract infection [5] . However, as pyuria is frequently absent, it is hypothesized that haematogenous spread is an alternative mechanism for infection [6] .
At the moment, there is no evidence-based treatment to guide clinicians in the management of renal cyst infection in ADPKD patients [7] . To fill this gap in knowledge, we performed a systematic review identifying all reports describing renal cyst infections in individual ADPKD patients. Based on these data, we identified treatment preferences and potential factors that could affect treatment outcome.
M A T E R I A L S A N D M E T H O D S

Data sources and searches
For this literature review, we applied a systematic search strategy using an extensive set of search queries (Supplementary data, Table S1 ). The electronic databases of PubMed (January 1948-February 2014), EMBASE (January 1974 -February 2014 and the Cochrane Library (until February 2014) were used. Reference lists of retrieved articles were manually searched for additional publications. Table S2 ) [8] .
Study selection
Publications were identified using predefined selection criteria. We focused on ADPKD patients (!18 years) who received renal cyst infection treatment. We used a citation management programme [EndNote, version X5.0.1. Thomson Reuters (Scientific) LLC, New York, NY, USA] to export our search results. M.A.L. and A.G. independently reviewed titles and abstracts. English, Dutch, French or German publications of any design were included. Articles that met the selection criteria and could be retrieved for full text evaluation were independently assessed by M.A.L. and A.G. We excluded studies when treatment could not be traced back to the individual patient, a malignant cyst was suspected or cyst intervention preceded cyst infection. Disagreement between M.A.L. and A.G. was resolved by discussion.
Data extraction and quality assessment
We collected variables on study design, patient characteristics, diagnosis and treatment. M.A.L., N.F.C. and A.G. extracted data. M.A.L. and N.F.C. independently reviewed data for completeness and accuracy. We assessed initial antimicrobial regimen duration and timing of invasive treatment following antimicrobial treatment. We defined antimicrobial regimens as consisting of monotherapy or combination therapy. Percutaneous and invasive treatments were defined as procedures with a known therapeutic effect even if the procedure was performed for diagnostic purposes [3] .
Treatment failure was defined as any treatment modification independent of reported outcome, such as switching or adding antimicrobial therapy or switching between treatment modalities. We defined recurrent cyst infection as recurrence of symptoms and restart of treatment after a treatment and a symptomfree interval of >1 week. Deaths were considered contributable to cyst infection in cases where the authors of the original article stated so. We did not contact study authors for additional information.
For sensitivity analyses, we compared our results with two case series without individual patient data available. This allowed us to investigate the presence of selection bias, since the most severe renal cyst infection cases are more likely to be discussed separately in the literature. In addition, we reviewed their definitions for diagnosis, treatment and recurrence.
FIGURE 1: Search strategy and article selection. ADPKD, autosomal dominant polycystic kidney disease; n, number. M a n a g i n g r e n a l c y s t i n f e c t i o n i n A D P K D
Data synthesis and analysis
Definite cyst infection was defined as the isolation of a pathogen from cyst aspirate [9] . As there are no uniform criteria for the diagnosis of probable cyst infection, we included all remaining cases under the diagnosis of probable infection [9] 
R E S U L T S
Study selection
The literature search identified 5590 citations ( Figure 1 ). We evaluated 475 full texts, of which 424 did not meet our inclusion criteria. Manual searching of references revealed nine additional studies. In total, we included 60 studies describing 85 ADPKD patients with a renal cyst infection. Detailed information on the individual cases is shown in Supplementary data, Tables S3 and S4.
Patient characteristics
We identified 85 ADPKD patients with a definite or probable renal cyst infection (Table 1) . Patients were 52 6 12 years old and predominantly female (55%). A positive cyst aspirate culture (i.e. definite cyst infection) was reported in 49% of patients. Escherichia coli grew in 50% of cyst aspirates (Supplementary data, Table S5 ). Impaired renal function was frequent, 79% of the patients had an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 , of which 27% were on dialysis and 13% had a renal transplantation. Furthermore, Table 1 shows patient and microbiological characteristics categorized by time period. No significant differences were found between patients treated before and during and after the year 2000.
Treatment options
Overall 160 treatments were performed: 92 antimicrobial, 29 percutaneous and 39 surgical ( Table 2 ). Details on treatment regimen were available in 77% of antimicrobial-treated patients. Overall, quinolone-based regimens were favoured (34%). Prior to the year 2000, significantly more patients were treated with a penicillin (31 versus 21%, P ¼ 0.02), whereas during and after 2000, almost half of the antimicrobial regimens contained a 
27 ( 
The median duration of antimicrobial treatment was 14 days (IQR: 6-28 days), and was significantly longer (P ¼ 0.006) during and after the year 2000. In addition, median time until invasive treatment was significantly longer during and after 2000 (20 versus 28 days, P ¼ 0.04).
Overall, 29 percutaneous treatments were performed. Percutaneous treatment consisted of cyst puncture, drainage and cyst aspiration. Regardless of the point in time after the diagnosis of infection, the majority of percutaneous treatments were combined with antimicrobials (overall: 83%; before 2000: 86%; and during and after 2000: 82%). Percutaneous therapy was significantly more often performed during and after the year 2000 (10 versus 25%, P ¼ 0.04).
Surgical treatments included cyst drainage, cyst fenestration, cyst decortication, cyst resection and nephrectomy. Overall, nephrectomy was the most frequently reported procedure, accounting for 79% of surgeries (Table 2 ). In recent years, significantly fewer nephrectomies were performed (25 versus 15%, P ¼ 0.03).
Therapy strategy and treatment failure Table 3 provides an overview of therapies that were instituted and success rates of initial therapy. Initial management predominantly consisted of antimicrobials (79%). Before 2000, initial therapy failed in 75% of the cases, compared with 51% during and after 2000 (P ¼ 0.03). Overall, antimicrobials were the final therapy in 28% of cases. During and after 2000, significantly more percutaneous therapies (P ¼ 0.001) and significantly fewer surgical procedures (P ¼ 0.002) were performed.
Only in 39% of patients, initial therapy led to effective management of cyst infection (Table 4 ). In patients with initial treatment failure (n ¼ 52), impaired function of the native kidneys was common (77% had an eGFR <60 mL/min/1.73 m 2 , of which 25% received dialysis and 10% had a renal transplantation). Urolithiasis (6%) or large cysts (diameter !5 cm, 27%) were frequently reported in patients with initial treatment failure. In such patients, the median duration of initial antimicrobial treatment was only 7 days, despite the antimicrobial resistance that was seen in 13%. Atypical pathogens (i.e. other than E. coli) were cultured in 54% of patients failing initial treatment.
In patients initially receiving antimicrobials (n ¼ 67), surgery was the final therapy in 37% (n ¼ 25) (Table 3 and Supplementary data, Table S6 ). If initial treatment consisted of percutaneous treatment (n ¼ 6), 17% (n ¼ 1) required additional invasive treatment.
Recurrence and cyst infection-related death
Six patients developed recurrent renal cyst infection (7%), of which four patients received dialysis (67%, Table 5 ). Except for one patient, these patients had initially been treated with antimicrobials. The median time of recurrence was 2 weeks (IQR: 2-9 weeks). Ultimately, six patients died because of renal cyst infection-related complications, three of whom were on dialysis Nephrectomy was the only procedure that was classified as a total resection. M a n a g i n g r e n a l c y s t i n f e c t i o n i n A D P K D
Three patients who ultimately developed septic shock, multi-organ failure or bowel perforation received antimicrobials as first-line therapy. The remaining three cases died as a result of surgical complications.
Sensitivity analysis
As a sensitivity analysis, we compared our study results with two case series with !10 ADPKD patients, which did not report individual patient data as needed for our systematic review [3, 11] . One study reported 15 cases of renal cyst infection [11] and the other documented 31 cases [3] . We compared the pooled data from these studies (n ¼ 46) with our cases (n ¼ 85) (Supplementary data, Table S7 ). Despite the fact that our case series contained significantly more definite cyst infections (49 versus 22%, P ¼ 0.002), initial treatment failure rates did not differ significantly between our series and the pooled data (61 versus 52%, P ¼ 0.2). Our cases more frequently received percutaneous treatment (P ¼ 0.005) and surgery (P < 0.001) as final treatment at the cost of antimicrobial therapies (P < 0.001). This indicates that in the present review, patients with a relatively severe renal cyst infection are included, who are potentially more prone to fail initial treatment.
Lastly, we compared our definitions for diagnosis, treatment and recurrence of renal cyst infection with those of the other two above-mentioned case series ( Table 6 ). The table shows that there is heterogeneity between diagnostic and treatment outcome criteria, which limits the ability to pool data from these series with our individual ADPKD cases. Neither paper included a definition for renal cyst infection recurrence.
D I S C U S S I O N
This systematic review shows that ADPKD patients with renal cyst infection present with a range of comorbid conditions, causative pathogens and other clinical factors. These differences in clinical presentation likely merit different initial treatment strategies. Antimicrobial therapy was the first step in 79% of cases and was associated with a high rate of failure (75%), 
eventually leading to either percutaneous intervention (27%) or surgery (37%). We found that treatment success rates increased significantly over time (25 versus 49%, P ¼ 0.03). Notwithstanding, recurrence and even cyst infection-related mortality still occurred in a number of cases in the most recent period studied. We identified several factors that could have potentially affected antimicrobial treatment outcome in our series. First, we detected a high rate of renal impairment (eGFR Stage III-V) among those failing initial treatment (42%). In patients with chronic renal insufficiency, inadequate arterial perfusion of the renal parenchyma could result in insufficient drug concentrations in both parenchyma and urine [12] . The efficacy of some antimicrobials, such as trimethoprim-sulfamethoxazole, an antimicrobial that is recommended for renal cyst infection [7] , is decreased in patients with impaired renal function [12] . Therefore, we suggest taking renal function into consideration when choosing an antimicrobial for initial treatment. Second, the duration of antimicrobial treatment was significantly shorter in patients with treatment failure and success rates were higher in recently published cases. One possible explanation is the longer duration of treatment in cases published during and after 2000 (7 versus 15 days). Third, we found that urolithiasis, post-renal obstruction or a cyst diameter !5 cm were reported in patients with initial treatment failure. Larger cysts might affect antimicrobial efficacy because of low intracystic concentrations [3, 13, 14] . As a result, this could potentially increase the risk of treatment failure. Presence of urolithiasis and postrenal obstruction are known as potential risk factors for developing cyst infection [15] . In patients without ADPKD, urolithiasis and post-renal obstruction complicate treatment due to an increased risk of antimicrobial resistance [16] . It is hypothesized that urolithiasis and post-renal obstruction lead to the development of a pathogen reservoir, potentiating the risk of antimicrobial failure. Indeed, we found that urolithiasis (5%) and post-renal obstruction (1%) were present in some cases. Lastly, it is clinical experience that urine and blood cultures in renal cyst infection often remain sterile, even in patients with a positive cyst aspirate [3] . This leads to an antimicrobial regimen that cannot be adapted according to the resistance pattern of cultured pathogens. In our series, we found that only in 12% of patients did microbiological cultures fail to identify the causative pathogen, without a difference between patients who failed treatment or not. Thus, inability to culture the causative pathogen has no important effect on outcome of initial therapy.
This study has strengths and limitations. Strengths include its systematic character, identifying 85 published ADPKD patients with renal cyst infection on an individual patient level, and its comprehensive overview of treatment strategies. A limitation is that our search result was limited to case series and case reports. This may have introduced outcome reporting bias. However, in a sensitivity analysis, we did not detect a significant difference in the rate of treatment failure between our case series and the pooled data of two case series without individual patient level data (61 versus 52%, P ¼ 0.2). We therefore consider our data to provide an adequate representation of renal cyst infection in ADPKD. Moreover, our data set did not allow us to investigate the effect of immunosuppressive drugs and other factors affecting immune status (e.g. age, nutritional status, dialysis duration, activities of daily living and kidney volume) on treatment outcome. Lastly, we applied our own criteria in order to assess treatment failure. This could have resulted in over-or underestimation of failure rate. However, to facilitate equal 
evaluation, we chose to assess each case using predefined uniform definitions (Table 6) . By performing this systematic review, we tried to identify gaps in knowledge and provide evidence-based treatment advice for the management of renal cyst infection in ADPKD patients [7] . Based on the available data, we identified factors that could potentially contribute to treatment failure. Unfortunately, there is limited evidence to support a specific algorithm for treatment. Such an algorithm may aid clinicians when confronted with a clinical suspicion of renal cyst infection in a patient with ADPKD. Since renal cyst infection is often difficult to treat and may result in death [3, 4] , we do suggest managing renal cyst infection in a hospitalized setting, if the necessary resources are available. When antimicrobial treatment does not lead to improvement, and alternative diagnoses and potential risk factors for treatment failure are ruled out, we suggest contacting a polycystic kidney disease expertise centre, i.e. a medical centre with special interest and experience in invasive treatment options for the multidisciplinary management of cyst infection in ADPKD, for advice or admitting the patient for further treatment. To optimize the treatment of renal cyst infections, a large prospective multicentre registry is needed. A registry study offers the opportunity to fill in gaps in knowledge through international collaboration [17] . Such a registry, in which all cases with presumed cyst infection are included in an unbiased manner, will allow development of the optimal evidence-based treatment strategy for this condition.
In conclusion, antimicrobial treatment for renal cyst infection in ADPKD is associated with a high rate of failure. The available evidence limits the identification of risk factors for treatment failure. To develop an algorithm for renal cyst infection treatment, a large clinical registry is needed.
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